Close
Close
Finance News

Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights

4.5
4.5 from 2 votes
Tuesday, November 14, 2017

Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, reported financial results for the third quarter ended September 30, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EST.

"The third quarter of 2017 was highlighted by encouraging interim results for the first cohort of adult patients dosed in the Phase 1/2 clinical trial of FCX-007, our product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating genetic skin disease with high mortality," said John Maslowski, President and Chief Executive Officer of Fibrocell. "In addition, we are working to complete the remaining pre-clinical activities for FCX-013 for the treatment of moderate to severe localized scleroderma and expect to file an Investigational New Drug (IND) application in the fourth quarter of this year."

Recent program highlights and new updates are as follows:

FCX-007

In September, Fibrocell reported interim results from the Phase 1 portion of its Phase 1/2 clinical trial of FCX-007 for the treatment of RDEB. Data from three adult NC1+ patients showed FCX-007 was well-tolerated through 12 weeks post-administration. No serious adverse events and no product-related adverse events were reported. In addition to encouraging interim safety data, positive early trends were noted in wound healing and pharmacology signals. The Data Safety Monitoring Board for the trial reviewed the interim data and concluded that safety and potential benefit were established, and allowed continuation of enrollment and dosing.
Fibrocell expects to perform additional dosing of adult patients in the Phase 1 portion of the clinical trial in the fourth quarter of 2017.
An RDEB adult has been enrolled as the first patient in the Phase 2 portion of the Phase 1/2 trial of FCX-007. Furthermore, upon obtaining allowance from the U.S. Food and Drug Administration (FDA), the Company expects to initiate enrollment of pediatric patients in the Phase 2 portion of the trial in the first quarter of 2018.
Fibrocell's existing, current good manufacturing practices (cGMP) cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 after incorporation into the IND. The facility will be used for the remaining clinical and future commercial manufacture of FCX-007, with capacity to serve the U.S. market for RDEB. The ~13,000 square foot facility previously supported commercial autologous fibroblast manufacturing, with multiple FDA inspections conducted at the site. The facility includes cleanroom cell therapy manufacturing, quality control testing, cryogenic storage, shipping/receiving and warehousing space.

FCX-013

Fibrocell initiated the good laboratory practices (GLP) toxicology/biodistribution study of FCX-013, performed dosing, and advanced into follow-up evaluations during the third quarter of 2017 that continue to progress in the fourth quarter of this year.
Based on the progress of pre-clinical development, Fibrocell expects to submit an IND application for FCX-013 to the FDA in the fourth quarter of 2017, and initiate a human safety clinical trial in 2018.

Financial Results for the Nine Months Ended September 30, 2017

For the nine months ended September 30, 2017, Fibrocell reported a diluted net loss of $1.58 per share, compared to a diluted net loss of $0.94 per share for the same period in 2016.

The 2017 period included approximately $4.7 million of non-cash warrant revaluation expense, as compared to approximately $10.5 million of non-cash warrant revaluation income for the same period in 2016. Additionally, the 2017 period included non-cash deemed dividends on Series A preferred stock of approximately $4.0 million increasing net loss attributable to common stockholders. No non-cash deemed dividends were recorded in the same period in 2016.

Research and development expenses decreased 4.4% to approximately $9.0 million for the nine months ended September 30, 2017, as compared to approximately $9.4 million for the same nine-month period in 2016. This decrease was due primarily to reduced compensation and employee related expenses in the 2017 period as a result of our restructuring related initiatives implemented in June 2016 in connection with the wind-down of our azficel-T operations. This decrease was partially offset by the increased costs related to the Phase 1/2 clinical trial of FCX-007 for the treatment of RDEB and pre-clinical development of FCX-013 for the treatment of moderate to severe localized scleroderma.

Selling, general and administrative expenses decreased 36.2% to approximately $5.1 million for the nine months ended September 30, 2017, as compared to approximately $8.0 million for the same nine-month period in 2016. This decrease was due primarily to reduced compensation and employee related expenses.

As of September 30, 2017, the Company had cash and cash equivalents of approximately $11.9 million and working capital of approximately $8.7 million. Fibrocell used approximately $12.9 million in cash for operations during the nine months ended September 30, 2017, as compared to approximately $25.6 million used for the same nine-month period in 2016.

The Company believes that its cash and cash equivalents at September 30, 2017 will be sufficient to fund operations into the second quarter of 2018.

Conference Call and Webcast

To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 9063692 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.

About Fibrocell

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell's most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell's gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.

Source: Fibrocell Science, Inc.
4.5
4.5 from 2 votes
Free Newsletter
Videos
by Scott Harwood
17 views
by Abidemi Uruejoma
17 views
by Scott Harwood
17 views